Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

GLP-1 receptor agonists such as semaglutide and liraglutide promote significant weight loss and improved glycemic control, ...

Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss. A study presented at ENDO 2025 showed a significant increase in ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 ...

Over a mean 2.2 years, the GLP1-RA group had significantly lower annual rates of acute healthcare utilization per patient (1.52 vs 1.67 events) and all-cause deaths (17.7% vs 20.5%) compared with ...

The findings of this study suggest that patients with GIP/GLP-1 RA prescriptions were less likely to experience opioid overdose and alcohol intoxication than those without such prescriptions. This ...

Individuals with type 2 diabetes who receive treatment with GLP-1 RAs do not have an increased risk for acute pancreatitis.

Before adjustment, for example, the GLP-1 RA group tended to be older (median 74 vs 67) and had more comorbidities like CKD (46.5% vs 33.2%) and coronary artery disease (70.1% vs 58.1%).

Within the subclass of GLP-1 RAs, semaglutide increased the most, from 0.2 to 4.4% from 2018 to 2023. Within one year, tirzepatide, which was approved in 2022, reached 1.3%.

The analysis included 18,016 kidney transplant recipients with diabetes (2013 through 2020) covered by Medicare, of whom 10.9% had at least one GLP-1 RA prescription filled posttransplant.

Among 220,822 patients with T2D who were included in the study, there were 47,526 GLP-1 RA users, 32,203 thiazolidinedione users, 30,682 combination therapy users, and a matched nonuser control group.